{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T03:03:11Z","timestamp":1789441391977,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,14]]},"DOI":"10.7759\/cureus.116245","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:16:56Z","timestamp":1789438616000},"source":"Crossref","is-referenced-by-count":0,"title":["Modern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists"],"prefix":"10.7759","author":[{"given":"Dorota","family":"Bartkowiak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barlomiej","family":"Jakubczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Lasota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Kopoczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Wiesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Wodzinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Boguszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Porazinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"M\u0142ynarska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Ratajski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2025.07.017","article-title":"American Association of Clinical Endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity\/adiposity-based chronic disease: 2025 update","volume":"31","author":"Nadolsky K","year":"2025","unstructured":"Nadolsky K, Garvey WT, Agarwal M, et al.. American Association of Clinical Endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity\/adiposity-based chronic disease: 2025 update. Endocr Pract. 2025, 31:1351-94. 10.1016\/j.eprac.2025.07.017","journal-title":"Endocr Pract"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-05906-7","article-title":"The expanding incretin universe: from basic biology to clinical translation","volume":"66","author":"Drucker DJ","year":"2023","unstructured":"Drucker DJ, Holst JJ. The expanding incretin universe: from basic biology to clinical translation. Diabetologia. 2023, 66:1765-79. 10.1007\/s00125-023-05906-7","journal-title":"Diabetologia"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae508","article-title":"Obesity and cardiovascular disease: an ESC clinical consensus statement","volume":"45","author":"Koskinas KC","year":"2024","unstructured":"Koskinas KC, Van Craenenbroeck EM, Antoniades C, et al.. Obesity and cardiovascular disease: an ESC clinical consensus statement. Eur Heart J. 2024, 45:4063-98. 10.1093\/eurheartj\/ehae508","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1254398","article-title":"Pharmacoeconomic evaluation of anti-obesity drugs for chronic weight management: a systematic review of literature","volume":"14","author":"Xue Y","year":"2023","unstructured":"Xue Y, Zou H, Ruan Z, et al.. Pharmacoeconomic evaluation of anti-obesity drugs for chronic weight management: a systematic review of literature. Front Endocrinol. 2023, 14:1254398. 10.3389\/fendo.2023.1254398","journal-title":"Front Endocrinol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck MA","year":"2018","unstructured":"Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018, 20:5-21. 10.1111\/dom.13129","journal-title":"Diabetes Obes Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck MA","year":"2022","unstructured":"Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022, 21:169. 10.1186\/s12933-022-01604-7","journal-title":"Cardiovasc Diabetol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne LJ","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW, et al.. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025, 393:26-36. 10.1056\/NEJMoa2416394","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0285197","article-title":"Weight loss efficiency and safety of tirzepatide: a systematic review","volume":"18","author":"Lin F","year":"2023","unstructured":"Lin F, Yu B, Ling B, et al.. Weight loss efficiency and safety of tirzepatide: a systematic review. PLoS One. 2023, 18:e0285197. 10.1371\/journal.pone.0285197","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-67701-9","article-title":"Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases","volume":"17","author":"Kong F","year":"2026","unstructured":"Kong F, Zhao Y, Zhang W, et al.. Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases. Nat Commun. 2026, 17:972. 10.1038\/s41467-025-67701-9","journal-title":"Nat Commun"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.250502","article-title":"Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update","volume":"197","author":"Pedersen SD","year":"2025","unstructured":"Pedersen SD, Manjoo P, Dash S, Jain A, Pearce N, Poddar M. Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update. CMAJ. 2025, 197:E797-809. 10.1503\/cmaj.250502","journal-title":"CMAJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-022-00783-3","article-title":"Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1","volume":"19","author":"Hammoud R","year":"2023","unstructured":"Hammoud R, Drucker DJ. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat Rev Endocrinol. 2023, 19:201-16. 10.1038\/s41574-022-00783-3","journal-title":"Nat Rev Endocrinol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1431292","article-title":"Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists","volume":"15","author":"Liu QK","year":"2024","unstructured":"Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists. Front Endocrinol. 2024, 15:1431292. 10.3389\/fendo.2024.1431292","journal-title":"Front Endocrinol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02319-7","article-title":"Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide","volume":"23","author":"Taktaz F","year":"2024","unstructured":"Taktaz F, Fontanella RA, Scisciola L, et al.. Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide. Cardiovasc Diabetol. 2024, 23:242. 10.1186\/s12933-024-02319-7","journal-title":"Cardiovasc Diabetol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2020.934","article-title":"Efficacy and safety of the new appetite suppressant, liraglutide: a meta-analysis of randomized controlled trials","volume":"36","author":"Moon S","year":"2021","unstructured":"Moon S, Lee J, Chung HS, Kim YJ, Yu JM, Yu SH, Oh CM. Efficacy and safety of the new appetite suppressant, liraglutide: a meta-analysis of randomized controlled trials. Endocrinol Metab. 2021, 36:647-60. 10.3803\/EnM.2020.934","journal-title":"Endocrinol Metab"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1085799","article-title":"GLP-1 receptor agonists for the treatment of obesity: role as a promising approach","volume":"14","author":"Wang JY","year":"2023","unstructured":"Wang JY, Wang QW, Yang XY, et al.. GLP-1 receptor agonists for the treatment of obesity: role as a promising approach. Front Endocrinol. 2023, 14:1085799. 10.3389\/fendo.2023.1085799","journal-title":"Front Endocrinol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey WT","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, et al.. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022, 28:2083-91. 10.1038\/s41591-022-02026-4","journal-title":"Nat Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey WT","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM, et al.. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023, 402:613-26. 10.1016\/S0140-6736(23)01200-X","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-05956-x","article-title":"Incretin hormones and type 2 diabetes","volume":"66","author":"Nauck MA","year":"2023","unstructured":"Nauck MA, M\u00fcller TD. Incretin hormones and type 2 diabetes. Diabetologia. 2023, 66:1780-95. 10.1007\/s00125-023-05956-x","journal-title":"Diabetologia"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan DH","year":"2024","unstructured":"Ryan DH, Lingvay I, Deanfield J, et al.. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024, 30:2049-57. 10.1038\/s41591-024-02996-7","journal-title":"Nat Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI194740","article-title":"The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications","volume":"136","author":"Jalleh RJ","year":"2026","unstructured":"Jalleh RJ, Talley NJ, Horowitz M, Nauck MA. The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications. J Clin Invest. 2026, 136:e194740. 10.1172\/JCI194740","journal-title":"J Clin Invest"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2500106","article-title":"GLP-1 receptor agonists","volume":"394","author":"Rosen CJ","year":"2026","unstructured":"Rosen CJ, Ingelfinger JR. GLP-1 receptor agonists. N Engl J Med. 2026, 394:1313-24. 10.1056\/NEJMra2500106","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-023-01382-9","article-title":"Real-world evaluation of GLP-1 receptor agonist therapy persistence, adherence and therapeutic inertia among obese adults with type 2 diabetes","volume":"14","author":"Palanca A","year":"2023","unstructured":"Palanca A, Ampudia-Blasco FJ, Calder\u00f3n JM, et al.. Real-world evaluation of GLP-1 receptor agonist therapy persistence, adherence and therapeutic inertia among obese adults with type 2 diabetes. Diabetes Ther. 2023, 14:723-36. 10.1007\/s13300-023-01382-9","journal-title":"Diabetes Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03765-w","article-title":"Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO)","volume":"31","author":"McGowan B","year":"2025","unstructured":"McGowan B, Ciudin A, Baker JL, et al.. Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO). Nat Med. 2025, 31:3229-32. 10.1038\/s41591-025-03765-w","journal-title":"Nat Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.71366","article-title":"Efficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Njei B","year":"2024","unstructured":"Njei B, Al-Ajlouni Y, Lemos SY, Ugwendum D, Ameyaw P, Njei LP, Boateng S. Efficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials. Cureus. 2024, 16:e71366. 10.7759\/cureus.71366","journal-title":"Cureus"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar N","year":"2021","unstructured":"Sattar N, Lee MM, Kristensen SL, et al.. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021, 9:653-62. 10.1016\/S2213-8587(21)00203-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial","volume":"389","author":"Jastreboff AM","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Fr\u00edas JP, et al.. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023, 389:514-26. 10.1056\/NEJMoa2301972","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02107-5","article-title":"Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines","volume":"10","author":"Xiao W","year":"2025","unstructured":"Xiao W, Jiang W, Chen Z, et al.. Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines. Signal Transduct Target Ther. 2025, 10:74. 10.1038\/s41392-024-02107-5","journal-title":"Signal Transduct Target Ther"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511774","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment","volume":"393","author":"Wharton S","year":"2025","unstructured":"Wharton S, Aronne LJ, Stefanski A, et al.. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025, 393:1796-806. 10.1056\/NEJMoa2511774","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-023-00966-w","article-title":"A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings","volume":"6","author":"V\u00e9niant MM","year":"2024","unstructured":"V\u00e9niant MM, Lu SC, Atangan L, et al.. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024, 6:290-303. 10.1038\/s42255-023-00966-w","journal-title":"Nat Metab"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s44446-025-00038-y","article-title":"GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity","volume":"33","author":"Alharbi AG","year":"2025","unstructured":"Alharbi AG. GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity. Saudi Pharm J. 2025, 33:34. 10.1007\/s44446-025-00038-y","journal-title":"Saudi Pharm J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/527056-modern-obesity-treatment-efficacy-safety-and-future-directions-of-glp-1-glucagon-like-peptide-1-and-gip-glucose-dependent-insulinotropic-polypeptide-receptor-agonists","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:16:58Z","timestamp":1789438618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/527056-modern-obesity-treatment-efficacy-safety-and-future-directions-of-glp-1-glucagon-like-peptide-1-and-gip-glucose-dependent-insulinotropic-polypeptide-receptor-agonists"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.116245","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,14]]}}}